Follicular lymphoma
A Carbone, S Roulland, A Gloghini, A Younes… - Nature reviews Disease …, 2019 - nature.com
Follicular lymphoma (FL) is a systemic neoplasm of the lymphoid tissue displaying germinal
centre (GC) B cell differentiation. FL represents~ 5% of all haematological neoplasms and …
centre (GC) B cell differentiation. FL represents~ 5% of all haematological neoplasms and …
Follicular lymphoma: 2020 update on diagnosis and management
A Freedman, E Jacobsen - American journal of hematology, 2020 - Wiley Online Library
Disease overview Follicular lymphoma (FL) is generally an indolent B cell
lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma is …
lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma is …
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
NH Fowler, M Dickinson, M Dreyling… - Nature medicine, 2022 - nature.com
Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor-T cell therapy with
clinically meaningful outcomes demonstrated in patients with relapsed/refractory (r/r) B-cell …
clinically meaningful outcomes demonstrated in patients with relapsed/refractory (r/r) B-cell …
Follicular lymphoma: 2023 update on diagnosis and management
E Jacobsen - American Journal of Hematology, 2022 - Wiley Online Library
Abstract Disease Overview Follicular lymphoma (FL) is generally an indolent B cell
lymphoproliferative disorder of transformed follicular center B cells. FL is characterized by …
lymphoproliferative disorder of transformed follicular center B cells. FL is characterized by …
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
C Casulo, JG Dixon, J Le-Rademacher… - Blood, The Journal …, 2022 - ashpublications.org
Observational studies and stand-alone trials indicate that patients with follicular lymphoma
(FL) who experience disease progression within 24 months of front-line …
(FL) who experience disease progression within 24 months of front-line …
NCCN guidelines insights: B-cell lymphomas, version 3.2019: featured updates to the NCCN guidelines
AD Zelenetz, LI Gordon, JS Abramson… - Journal of the National …, 2019 - jnccn.org
Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most
common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of …
common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of …
Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a …
C Casulo, MC Larson, JJ Lunde… - The Lancet …, 2022 - thelancet.com
Background Novel therapies for relapsed or refractory follicular lymphoma are commonly
evaluated in single-arm studies without formal comparison with other treatments or historical …
evaluated in single-arm studies without formal comparison with other treatments or historical …
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
F Morschhauser, S Dahiya, ML Palomba… - Nature Medicine, 2024 - nature.com
An unmet need exists for patients with relapsed/refractory (R/R) follicular lymphoma (FL) and
high-risk disease features, such as progression of disease within 24 months (POD24) from …
high-risk disease features, such as progression of disease within 24 months (POD24) from …
[HTML][HTML] Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: a consensus expert opinion statement
Patients undergoing evaluation for solid organ transplantation (SOT) frequently have a
history of malignancy. Only patients with treated cancer are considered for SOT but the …
history of malignancy. Only patients with treated cancer are considered for SOT but the …
Follicular lymphoma: The long and winding road leading to your cure?
Follicular lymphoma, the most common indolent lymphoma, though highly responsive to
therapy is coupled with multiple relapses for the majority of patients. Advances in biologic …
therapy is coupled with multiple relapses for the majority of patients. Advances in biologic …